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CD4 T-cell help is essential for effective immune responses to viruses. In human immunodeficiency virus
(HIV) infection, CD4 T cells specific for HIV are infected by the virus at higher frequencies than other
memory CD4 T cells. Here, we demonstrate that HIV-specific CD4 T cells are barely detectable in most
infected individuals and that the corresponding CD4 T cells exhibit an immature phenotype compared to both
cytomegalovirus (CMV)-specific CD4 T cells and other memory CD4 T cells. However, in two individuals,
we observed a rare and diametrically opposed pattern in which HIV-specific CD4 T-cell populations of large
magnitude exhibited a terminally differentiated immunophenotype; these cells were not preferentially infected
in vivo. Clonotypic analysis revealed that the HIV-specific CD4 T cells from these individuals were cross-
reactive with CMV. Thus, preferential infection can be circumvented in the presence of cross-reactive CD4 T
cells driven to maturity by coinfecting viral antigens, and this physical proximity rather than activation status
per se is an important determinant of preferential infection based on antigen specificity. These data demon-
strate that preferential infection reduces the life span of HIV-specific CD4 T cells in vivo and thereby
compromises the generation of effective immune responses to the virus itself; further, this central feature in the
pathophysiology of HIV infection can be influenced by the cross-reactivity of responding CD4 T cells.
CD4 T helper cells are crucial for the maintenance of
adaptive immunity. Specifically, CD4 T cells secrete cytokines
that orchestrate subsequent immune responses and support
homeostasis and CD4 T cells express costimulatory mole-
cules that promote antigen presentation. In addition, CD4 T
cells secrete cytokines and chemokines that have direct proin-
flammatory and antiviral properties. Indeed, the necessity of
appropriate CD4 T-cell responses for control of viral repli-
cation is well documented (12, 19, 24). While human immu-
nodeficiency virus (HIV) infection is relatively unique com-
pared to other viral infections in that HIV is neither cleared
nor controlled by the naturally elicited immune response, there
are accumulating data suggesting that the HIV-specific CD4
T-cell response is critical in controlling viral replication. First,
CD4T cells that respond to HIV stimulation are found at higher
frequencies in individuals classified as long-term nonprogressors
(32). Second, individuals with detectable HIV-specific CD4 T-
cell responses have a better prognosis after structured antiretro-
viral therapy interruptions (29, 33). Third, HIV-infected individ-
uals that maintain HIV-specific CD4 T cells capable of
producing interleukin-2 (IL-2) and proliferating have a better
prognosis than individuals that do not have HIV-specific CD4 T
cells capable of these effector functions (23, 44). Finally, HIV-
specific CD4 T-cell responses are negatively correlated with
disease progression (27). While HIV-specific CD4 T cells are
paramount in control of viral replication, these cells are prefer-
entially infected by the virus at all stages of infection (11, 14, 17).
The findings that HIV-specific CD4 T cells are preferen-
tially infected by the virus and that infected CD4 T cells are
less likely to reach terminal differentiation in vivo (5) led us to
question whether or not preferential infection impacts the abil-
ity of HIV-specific CD4 T cells to undergo rounds of stimu-
lation and proliferation required to increase precursor frequen-
cies to appreciable levels and reach terminal differentiation in
vivo. Indeed, earlier reports suggest functional and phenotypic
abnormalities within the HIV-specific CD4 T-cell pool. How-
ever, the causality of this phenomenon is unclear. Here, we at-
tempt to address this issue by a detailed study of phenotype and
magnitude of HIV-specific CD4 T cells compared to those of
cytomegalovirus (CMV)-specific CD4 T cells in a cohort of
HIV-infected individuals; in doing so, we relate observed inter-
individual differences to infection rates within CD4 T cells of
defined antigen specificity. In particular, a detailed analysis of
uncommon and atypical responses provided important clues to
mechanisms underlying the ability to circumvent preferential in-
fection and provided insight into vaccine modalities aimed at
stimulating HIV-specific CD4 T cells.
MATERIALS AND METHODS
Subjects. Twenty-three HIV- and CMV-dually infected and 11 CMV-infected
subjects were recruited at the National Institutes of Health (Table 1). Plasma
HIV load was determined using either a Roche Amplicor Monitor assay or a
Roche Ultradirect assay. Informed consent was obtained from all subjects prior
to entry into this study, which was approved by the NIH Institutional Review
Board.
Cell stimulation. Peripheral blood mononuclear cells (PBMC) were isolated
and in some instances viably cryopreserved until later use. Antigenic stimulation
was performed with fresh or frozen PBMC as previously described (2, 28).
Similar results from cell stimulation protocols were obtained using fresh or
frozen PBMC (7). In every experiment, a negative control (anti-CD28/CD49d, 1
g/ml final) was included to quantify spontaneous production of effector cyto-
kines, and a positive control (staphylococcus enterotoxin B, 1 g/ml final; Sigma,
St. Louis, MO) was included to ensure that cells were responsive to in vitro
stimulation. In all experiments, less than 0.1% of CD4 T cells produced effector
cytokine in the absence of specific stimulation. Overlapping peptides were used
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to stimulate HIV-specific T cells in the presence of brefeldin A (1 g/ml; Sigma)
for 5 h at 37°C. All cells were surface stained for phenotypic markers of interest
and intracellularly stained for cytokines.
Antigens. Fifteen-mer peptides overlapping by 11 amino acids corresponding
to sequences of a clade B HXBc2/Bal R5 chimeric HIV strain (Gag, Pol, Env,
and Nef) were pooled into mixtures grouped by HIV proteins as previously
described (2). Individual peptides were suspended in dimethyl sulfoxide at 10
mg/ml and diluted to a final concentration of 2 g/ml in all stimulations. CMV
whole antigen and control antigen complement fixation lysate preparations were
obtained from BioWhittaker (Walkersville, Maryland) and were used at 60 l/ml
for stimulations.
Immunofluorescence staining. Stimulated PBMC were washed and then
stained with directly conjugated antibodies to surface markers (Becton Dickin-
son Immunocytometry Systems [BDIS], San Jose, CA) for 20 min on ice. The
cells were washed and fixed/permeabilized for 10 min (fixation/permeabilization
solution; BDIS), stained with directly conjugated antibodies to gamma interferon
(IFN-), tumor necrosis factor (TNF), and IL-2 all conjugated to the same
fluorochrome, and resuspended in 1% paraformaldehyde in phosphate-buffered
saline. The use of monoclonal antibodies against three effector cytokines simul-
taneously increases the probability of identifying relevant antigen-responsive
CD4 T cells (28). Responses were considered to be antigen specific if respond-
ing cells represented greater than 0.1% of all CD4 T cells.
MHC-II tetramers. HLA DR 15*01 soluble tetramers loaded with either HIV
p24-4 (DRFYKTLRAEQASQ) or CLIP (PVSKMRMATPLLMQA) were pre-
pared as previously described and were a kind gift from Kai Wucherpfennig (9,
38). Major histocompatibility complex class II (MHC-II) multimers were then
added to at least one million lymphocytes at 10 g/ml at 37°C for 20 min. Cells
were then washed, stained with surface markers of interest, and analyzed imme-
diately.
Flow cytometric analysis. Six-parameter flow cytometric analysis was per-
formed using a FACSCalibur flow cytometer (BDIS). Fluorescein isothiocyanate
(FITC), phycoerythrin (PE), peridinin chlorophyll protein, and allophycocyanin
(APC) were used as the fluorophores. At least 100,000 live CD3 lymphocytes
were collected. Eight-parameter flow cytometric sorting and analysis were per-
formed using a FACS Aria flow cytometric cell sorter (BDIS). FITC, PE, APC,
Cascade Blue, and Cy7 APC were used as the fluorophores. The list mode data
files were analyzed using FlowJo software (Tree Star, Inc., San Carlos, CA).
Cell sorting. Cell sorting was accomplished using a FACS Aria cell sorter
(BDIS) at 70 lb/in2. FITC, PE, Cy5 PE, and APC were used as the fluorophores.
At least 10,000 cells were sorted for PCR and reverse transcriptase PCR analysis.
Sorted populations were consistently at least 99.8% pure.
qPCR. Quantification of HIV gag DNA in sorted CD4 T cells was performed
by quantitative PCR (qPCR) by means of a 5 nuclease (TaqMan) assay with an
ABI7700 system (PerkinElmer, Norwalk, CT) as previously described (5, 13). To
quantify cell number in each reaction, qPCR was performed simultaneously for
albumin gene copy number as previously described (14). Standards were con-
structed for absolute quantification of gag and albumin copy number and were
validated with sequential dilutions of 8E5 cell lysates that contain one copy of gag
per cell. Duplicate reactions were run and template copies calculated using
ABI7700 software.
Clonotypic analysis. Viable antigen-specific CD4 T cells were sorted based
upon capture of IFN- following antigen-specific stimulation with a CD45/IFN-
bispecific antibody as described previously (13). Clonotypic analysis was per-
formed as described previously by using a modified template switch anchored
reverse transcriptase PCR with a 3 constant region primer to amplify all ex-
pressed T-cell receptor -chain (TCRB) gene products without bias (13, 31).
Statistical analysis. Statistical significance was determined by a Mann-Whit-
ney test using Prism 3.0 software (Prism, San Diego, CA).
RESULTS
Small frequencies of circulating CD4 T cells are HIV spe-
cific. Studies suggest that HIV-infected individuals generally
do not maintain large populations of HIV-specific CD4 T
cells (28). This is counterintuitive because one would expect
that under conditions of chronic viral replication a high fre-
quency of antigen-specific CD4 T cells should be expanded in
the memory T-cell pool (14, 17, 28, 44). To explore these
observations further, we initially used intracellular cytokine
staining following antigenic stimulation with HIV Gag, Nef,
Env, or Pol or CMV whole antigen. Consistent with previous
studies, we found that significantly fewer CD4 T cells re-
sponded to HIV-specific stimulation than to CMV-specific
stimulation (Fig. 1). Here, individual responses to HIV Gag,
Nef, Env, and Pol are summed, as these proteins represent the
FIG. 1. Low frequencies of CD4 T cells respond to HIV antigenic
stimulation. PBMC from the HIV-infected subjects in the cohort were
stimulated with peptides 15 amino acids in length and overlapping by
11 amino acids and grouped according to antigen. Peptides encom-
passing HIV Gag, Env, Pol, and Nef were used as stimulants. PBMC
from all individuals were also stimulated with CMV whole antigen. In
addition, for six individuals, CMV responses after stimulation with
overlapping peptides encompassing CMV pp65 and IE1 are included
for completeness. Following stimulation for 5 h in the presence of
brefeldin A, cells were extracellularly stained for CD4, CD3, and CD57
and were intracellularly stained for TNF, IL-2, and IFN-. The per-
centages of CD4 T cells that responded with cytokine secretion are
displayed. HIV-specific CD4 T-cell responses represent summation
of responses to HIV Gag, Nef, Env, and Pol. Filled symbols represent
results for subjects 1 and 21. Horizontal bars represent medians.
TABLE 1. Subject cohort
Subject
no.
HIV
statusa
CD4
count Virus load HAART
1  304 200,000 No
2  459 129 No
3  157 61,400 No
4  394 57,200 No
5  491 6,400 No
6  939 3,900 No
7  636 50 Yes
8  471 800 Yes
9  636 2,500 No
10  884 50 Yes
11  327 125 Yes
12  297 5,600 No
13  145 3,200 Yes
14  100 185,200 No
15  552 21,900 No
16  602 12,500 No
17  343 200,000 No
18  316 376,200 No
19  400 71,000 No
20  708 50 Yes
21  1,058 2,600 No
22  652 31,400 No
23  469 7,500 No
24–34  NAb 0 No
a , positive; , negative.
b NA, not applicable.
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most immunogenic HIV proteins during chronic HIV infection
(1). Importantly, the frequency of responding HIV-specific
CD4 T cells in HIV-infected individuals was also significantly
smaller than the frequency of responding CMV-specific CD4
T cells in HIV CMV individuals, even though both cellular
and free viral loads were higher for HIV than for CMV (Fig.
1). Furthermore, there was no statistical difference between
the frequencies of CD4 T cells that respond to CMV when
comparing the HIV-infected individuals to the HIV-uninfected
individuals. However, CMV stimulation using whole antigen
lysate preparations is not necessarily directly comparable to
HIV-specific stimulations based upon overlapping peptide
stimulations. We therefore confirmed that significantly lower
frequencies of CD4 T cells respond to HIV stimulation than
to CMV stimulation by stimulating CD4 T cells from several
CMV-seropositive individuals with 15-mer overlapping pep-
tides encompassing CMV pp65 and IE1. While these proteins
are immunostimulatory in many individuals, this stimulation
protocol invariably results in an underrepresentation of the
total CMV-specific CD4 T-cell population (40). Nonethe-
less, the frequency of CD4 T cells that respond to these
two proteins of CMV is significantly higher than the fre-
quency of CD4 T cells that respond to HIV Gag, Env, Nef,
and Pol (Fig. 1).
Functionally defined HIV-specific CD4 T cells are not ter-
minally differentiated. Under normal circumstances, chronic
viral replication should result in clonal expansion of antigen-
specific CD4 T cells, as is the case for HIV-specific CD8 T
cells (6). While the ability of CD4 T cells to reach terminal
differentiation is substantially different from that of CD8 T
cells (36, 43), it is generally accepted that terminally differen-
tiated CD4 T cells accumulate in situations of chronic viral
infections and in the chronic stages of HIV infection (5, 17,
22). We measured surface CD57 expression to determine
whether or not HIV-specific CD4 T cells became terminally
differentiated in vivo compared to CMV-specific CD4 T cells
and other memory CD4 T cells (Fig. 2). HIV-specific CD4
T cells reach terminal differentiation at a significantly lower
frequency than CMV-specific (HIV-infected or HIV-unin-
fected) and other memory (HIV-infected) CD4 T cells, dem-
onstrating that terminally differentiated CD4 T cells that
accumulate in the peripheral blood of HIV-infected individu-
als do not respond to the virus itself. Importantly, there was no
difference between the frequencies of CMV-specific CD4 T
cells that reached terminal differentiation when comparing
HIV-infected and uninfected individuals (Fig. 2).
Physically defined HIV-specific CD4 T cells are not termi-
nally differentiated. Identification of antigen-specific CD4 T
cells from humans usually involves a functional readout after
antigen-specific stimulation. However, the recent advent of
soluble MHC-II multimers has allowed for physical identifica-
tion of antigen-specific CD4 T cells (9, 18, 35, 38). To ensure
that our analysis was not biased to detection of only HIV-
specific CD4 T cells capable of effector function, we utilized
HLA DR 15*01 tetramers to identify antigen-specific CD4 T
cells from subject 9 (known to express the HLA DR 15*01
allele and respond to the p24-4 peptide) (Fig. 3). Lymphocytes
were stained with tetramers binding either Gag peptide or
CLIP peptide as a negative control and then stained for surface
molecules of interest. For this individual, no CD4 T cells
specific for p24-4 became terminally differentiated in vivo. We
were unable to identify HIV-specific CD4 T cells with HLA
DR 15*01 tetramers for any other individuals in our cohort
due to limiting frequencies of responses to individual peptides
and lack of appropriate HLA haplotypes.
HIV-specific CD4 T-cell responses can be large and com-
posed of phenotypically mature T cells when preferential in-
fection is avoided. We further explored the impact of prefer-
ential infection by close examination of the magnitude and
corresponding phenotypes of the responding HIV-specific
CD4 T cells from the subjects in our cohort and observed that
two subjects were clearly outliers (Fig. 1 and 2). For these two
individuals (subjects 1 and 21), the CD4 T cells that re-
sponded to HIV antigens were of phenotype and magnitude
similar to those of CD4 T cells that responded to CMV
antigens (Fig. 4). In order to understand the unusual circum-
stances that allowed these two individuals to respond to HIV-
specific stimulation with such a large frequency of terminally
differentiated CD4 T cells, we sorted subsets of CD4 T cells
from these individuals (Fig. 4) and performed qPCR for HIV
DNA, which acts as a surrogate for in vivo infection history (5,
14) (Table 2). The responding HIV-specific CD4 T cells
sorted from these two individuals were infected at frequencies
similar to those of other memory CD4 T cells, demonstrating
that the HIV-specific CD4 T cells of these two subjects were
not preferentially infected by HIV. In contrast, and consistent
with our previous studies and those of others (11, 14, 17), the
HIV-specific CD4 T cells from subject 19 were preferentially
infected (Table 2).
Clonotypic analysis of CMV- and HIV-specific CD4 T cells.
Although subjects 1 and 21 both had high frequencies of ter-
minally differentiated, HIV-specific CD4 T cells, both sub-
jects failed to control viral replication. Moreover, subject 1
progressed to AIDS (Table 1). In any event, the ability of these
two individuals to respond to HIV-specific stimulation with a
high frequency of CD4 T cells in the absence of preferential
infection presented an opportunity to dissect the mechanistic
basis for these anomalous responses.
FIG. 2. CD4 T cells that respond to HIV-specific stimulation do
not reach terminal differentiation in vivo. PBMC from individuals in
the cohort were stimulated with HIV peptides and/or CMV whole
antigen. The percentage of responding antigen-specific CD4 T cells
that reached terminal differentiation was determined based upon ex-
pression of CD57. HIV-specific CD4 T-cell responses represent sum-
mation of responses to HIV Gag, Nef, Env, and Pol. Filled symbols
represent results for subjects 1 and 21. Horizontal bars represent
medians.
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To characterize further the nature of these CD4 T cells, we
first used epitope mapping based on matrix analysis (2) to
determine that subject 1 responded to a single 15-mer peptide
in HIV Gag p24 (EQIGWMTNNPPIPVG). We then used this
single HIV 15-mer peptide to stimulate HIV-specific CD4 T
cells from subject 1. In addition, in a parallel experiment we
stimulated CMV-specific CD4 T cells from the same individ-
ual. For both antigen-specific responses, we viably sorted the
responding T cells by utilization of an antibody bispecific for
IFN- and CD45 (13). Cells that captured IFN- and ex-
pressed CD69 were then separated and sorted based on CD57
expression. We then determined the clonotypic composition of
the responding CMV- and HIV-specific CD4 T cells by se-
quencing the CDR3s of all expressed TCRB genes (Fig. 5) as
previously described (13, 31). In addition, in a separate exper-
iment we sorted CD57 CD4 T cells from this individual
without regard to their antigen specificity and performed clo-
notypic analysis (Fig. 5A).
From this analysis, we were surprised to find that the HIV-
specific CD4 T cells from subject 1 were clearly cross-reactive
with CMV. Importantly, the bulk CD57 CD4 T-cell subset
from this individual was composed of two dominant clonotypes
(Fig. 5A). The CMV-specific CD4 T cells were also domi-
nated by these same two clonotypes, suggesting that all CD57
CD4 T cells from this individual were CMV specific (Fig. 5B).
One of these predominant clonotypes also responded to HIV-
specific stimulation (Fig. 5C). This dominant clonotype found
within HIV- and CMV-specific CD57 CD4 T cells was also
found in both HIV- and CMV-specific CD57 CD4 T cells
(Fig. 5D and E). In order to confirm that this dominant clono-
type was expressed by a cross-reactive T-cell clone (and not
two different T-cell clones expressing the same TCRBV), we
also sequenced the TCRA region and found exactly the same
sequences between T cells sorted after stimulation with CMV
or HIV (data not shown). We found no sequence homologies
between the HIV epitope and the CMV proteome and were
therefore unable to identify the individual CMV epitope. How-
ever, cross-reactivity can exist among epitopes that share no
primary structure similarities (42). While we were unable to
determine the relative affinities that these cross-reactive T cells
have for the CMV and HIV epitopes, we were able to deter-
mine that the T cells could respond to the HIV epitope at
concentrations as low as 0.0125 g/ml (data not shown).
In addition, we performed epitope mapping from subject 21
(the other individual that was able to maintain HIV-specific
CD4 T cells that avoided preferential infection). In stark
contrast to subject 1, subject 21 responded to at least six
epitopes within HIV Gag (data not shown). Unfortunately, no
response was large enough to facilitate use of viable sorting in
order to perform clonotypic analysis. We therefore stimulated
FIG. 3. Physically identified HIV-specific CD4 T cells do not reach terminal differentiation in vivo. PBMC from subject 9 were surface stained
with soluble HLA DR 15*01 tetramers bound to either irrelevant peptide or HIV p24 DRFYKTLRAEQASQ. PBMC were then washed and
surface stained with anti-CD3, anti-CD4, anti-CD27, and anti-CD57. CD4 CD3 events are shown.
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CD4 T cells with peptides encompassing all of Gag for viable
sorting of antigen-specific CD4 T cells followed by clonotypic
analysis (Fig. 6). In a parallel experiment, we sorted CD4 T
cells that responded to CMV-specific stimulation followed by
clonotypic analysis (Fig. 6). While the CMV-specific CD4 T
cells from this individual were oligoclonal, dominated by three
clonotypes, the HIV-specific CD4 T cells were extremely
polyclonal, and of this polyclonal repertoire one clone was
cross-reactive with CMV.
DISCUSSION
In the present study, we have examined the magnitudes,
maturational phenotypes, clonotypic structures, and HIV in-
fection frequencies of CD4 T-cell populations that respond to
HIV-derived antigens. The principal findings were as follows:
(i) in the majority of HIV-infected individuals, the frequency
of HIV-specific CD4 T cells is small and the responding cells
do not reach terminal differentiation in vivo despite chronic
exposure to high levels of antigen; (ii) in a rare minority of
HIV-infected individuals, high frequencies of terminally dif-
ferentiated HIV-specific CD4 T cells can be detected; (iii)
these large, phenotypically mature populations of HIV-specific
CD4 T cells are not preferentially infected by HIV; and (iv)
this lack of preferential infection is associated with HIV-spe-
cific CD4 T-cell clonotype cross-reactivity with CMV. Taken
together, these data indicate that preferential infection ad-
versely affects the HIV-specific CD4 T-cell response to a
substantial extent and provide evidence that proximity of HIV-
specific CD4 T cells to antigen-presenting cells that present
HIV-derived epitopes and perhaps infectious HIV virions dur-
ing antigen presentation in vivo is involved in this process.
FIG. 4. HIV-specific CD4 T cells can be present at high frequencies and composed of terminally differentiated CD4 T cells. PBMC from
subjects 1 and 21 were stimulated with Gag peptides or CMV whole antigen. Following stimulation for 5 h in the presence of brefeldin A, cells
were extracellularly stained with CD4, CD3, and CD57 and were intracellularly stained for TNF, IL-2, and IFN-. CD4 CD3 events are shown.
TABLE 2. Cell-associated viral DNA
Subject
no. T-cell subset
Frequency of viral DNA/105
sorted cells (% infected)
1 CD57 memory 1,388 (1.39)
CD57 memory 209 (0.2)
CD57 HIV specific 248 (0.25)
CD57 HIV specific 54 (0.05)
CD57 CMV specific 575 (0.58)
CD57 CMV specific 114 (0.11)
21 CD57 memory 580 (0.58)
CD57 memory 254 (0.25)
CD57 HIV specific 705 (0.7)
CD57 HIV specific 388 (0.39)
19 CD57 memory 779 (0.8)
CD57 memory 82 (0.082)
CD57 HIV specific 2,337 (2.3)
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Historically, CD4 T-cell responses to HIV-derived anti-
gens have been difficult to detect in infected individuals. While
early attempts were potentially limited by methodological con-
straints (8, 41), more sensitive techniques that can be applied
directly ex vivo have generally confirmed these initial observa-
tions (28). However, it is also clear that, under certain circum-
stances, HIV-specific CD4 T-cell responses of substantial
magnitude can be present in the peripheral blood of infected
individuals. For example, during primary HIV infection, vig-
orous CD4 T-cell responses to HIV-derived antigens can be
detected frequently (26, 32); these can be transient in nature or
more sustained and tend to be preserved in the short term by
the early administration of highly active antiretroviral therapy
(HAART) (20, 26, 33). Similarly, substantial HIV-specific
CD4 T-cell responses have been observed with long-term
nonprogressors (3) and with individuals with “discordant” re-
sponses to HAART, in whom virologic breakthrough is asso-
ciated with drug-resistant HIV typically exhibiting impaired
FIG. 5. Clonotypic analysis of HIV- and CMV-specific CD4 T cells from subject 1. PBMC from subject 1 were stimulated with Gag
EQIGWMTNNPPIPVG or CMV whole antigen in the presence of a CD45/IFN- bispecific antibody. Following stimulation for 5 h, cells were
extracellularly stained with CD4, CD3, CD57, and IFN-. IFN--producing cells were sorted based upon CD57 expression into RNAlater followed
by unbiased anchored template switch PCR to identify all expressed TCRB genes. freq, frequency.
6806 BRENCHLEY ET AL. J. VIROL.
 o
n
 February 23, 2018 by CARDIFF UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
replicative capacity (10, 30); in addition, transient boosting of
CD4 T-cell responses to HIV Gag peptides has been ob-
served after discontinuation of antiretroviral therapy (28).
Overall, these observations suggest that an intimate balance
prevails in vivo in which antigenic stimulation drives CD4
T-cell proliferation but is counteracted by destructive effects
mediated by HIV. The mechanistic basis for this destructive
effect has been attributed to the phenomenon of preferential
infection (11, 14, 15, 17). Indeed, it is clear that HIV infects
HIV-specific CD4 T cells at a higher frequency than CD4 T
cells of other specificities under most circumstances (14). Thus,
the presence of HIV-specific CD4 T cells in infected individ-
uals could be either beneficial, through the provision of cog-
nate help to humoral and CD8 T-cell responses, or disadvan-
tageous, through the provision of target cells that could serve
to amplify HIV replication in vivo. The literature reflects this
level of uncertainty, with previous studies providing evidence
that could be interpreted as being consistent with either effect
(4, 25, 27, 32, 34, 39). In either eventuality, however, a more
detailed understanding of both the mechanisms that underlie
the process of preferential infection and the consequences of
this phenomenon could reveal important insights into HIV
pathogenesis.
In the present study, we examined CD4 T-cell responses to
overlapping peptides spanning HIV-1 Gag, Pol, Env, and Nef
in a cohort of 23 individuals with chronic HIV infection. Con-
sistent with previous studies, HIV-specific CD4 T cells in this
cohort were generally present at low frequencies (1% of the
total CD4 T-cell pool) in peripheral blood (Fig. 1). Notably,
phenotypic analysis revealed that these HIV-specific CD4 T
cells were relatively immature (Fig. 2 and 3); again, this is
consistent with previous observations (17, 45). These data sug-
gest that HIV-specific CD4 T cells have a shortened life span
in vivo compared to CD4 T cells with other antigen specific-
ities. However, it is important to appreciate that antigen-in-
duced activation per se could lead to CD4 T-cell death; thus,
the low frequency of phenotypically immature CD4 T cells
specific for HIV could simply reflect the consequences of im-
mune activation rather than any direct effects of the virus itself
(16). Observations from the two atypical responders in our
cohort helped to distinguish between these possible explana-
tions.
The HIV-specific CD4 T-cell responses in donors 21 and 1
were substantial (1% of the total CD4 T-cell pool) and
exhibited a mature phenotype exemplified by the expression of
CD57, which defines terminal differentiation and replicative
senescence in peripheral-blood T cells (5) (Fig. 4). Further, in
contrast to findings with the vast majority of infected individ-
uals, the HIV-specific CD4 T cells of these two donors were
not preferentially infected by HIV (Table 2). These observa-
tions indicate that HIV-specific CD4 T cells can accrue to
substantial levels in vivo and differentiate fully in the absence
of preferential infection. In addition, differences in plasma
virus load overall did not appear to account for the profoundly
FIG. 6. Clonotypic analysis of HIV- and CMV-specific CD4 T
cells from subject 21. PBMC from subject 21 were stimulated with
overlapping Gag peptides or CMV whole antigen in the presence of a
CD45/IFN- bispecific antibody. Following stimulation for 5 h, cells
were extracellularly stained with CD4, CD3, and IFN-. IFN--pro-
ducing cells were sorted into RNAlater followed by unbiased anchored
template switch PCR to identify all expressed TCRB genes. freq,
frequency.
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unusual nature of the HIV-specific CD4 T-cell responses in
these two donors compared with responses of the other indi-
viduals in the cohort (Table 1). Thus, preferential infection
shortens the life span of HIV-specific CD4 T cells irrespec-
tive of other effects related to viral replication.
To elucidate the mechanistic basis by which preferential
infection was circumvented in subjects 21 and 1, we undertook
a fine mapping study of individual epitope specificities within
the dominant HIV-specific responses and compared the clo-
notypic architecture of the responding CD4 T cells to the
contemporaneous CMV-specific CD4 T-cell responses. Re-
markably, within a relatively oligoclonal HIV-specific CD4
T-cell population that was focused almost exclusively on a
single Gag-derived epitope, the dominant clonotype also ap-
peared as the dominant CMV-specific CD4 T-cell clonotype
in subject 1 (Fig. 5). This applied to both CD57 and CD57
CD4 T-cell subsets for each specificity; since individual T-cell
clonotypes, by definition, are progeny of a single precursor,
these data are consistent with a linear maturation process.
Similar findings pertained to subject 21, although in this case
the responding HIV-specific CD4 T-cell population was more
polyclonal and targeted multiple Gag-derived epitopes (Fig.
6). As most individuals are exposed to CMV within the first 16
years of life, it seems likely that this prevalent clonotype was
initially selected and driven to terminal differentiation in the
periphery in response to CMV infection even before HIV
infection had occurred; the observed cross-reactivity with
HIV-1 Gag is, presumably, coincidental. These data suggest,
therefore, that preferential infection of HIV-specific CD4 T
cells can be circumvented in the presence of cross-reactive
CD4 T-cell clonotypes driven to maturity by coinfecting viral
antigens; this is consistent with previous studies in which it has
been shown that terminally differentiated CD4 T cells are less
likely to become infected by HIV in vivo (5). In a broader
context, these data demonstrate a biological relevance for T-
cell cross-reactivity in humans, a phenomenon that has been
reported previously only with murine models (21, 37).
In summary, we have provided strong evidence that the
process of preferential infection reduces the life span of HIV-
specific CD4 T cells in vivo. Furthermore, the data indicate
that the clonotypic nature of the responding T cells, influenced
by the infection history of the individual, can affect this pro-
cess. While it is clear that a high frequency of terminally dif-
ferentiated HIV-specific CD4 T cells is not sufficient in itself
to control viral replication, these findings illuminate a basic
pathophysiological process that likely impacts the outcome of
HIV infection.
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